PRCT vs TFX
PRCT: A surgical robotics company revolutionizing the treatment of benign prostatic hyperplasia (BPH) with its proprietary, image-guided waterjet ablation system. TFX: Teleflex provides essential, specialty medical technologies used in critical care and surgical procedures to improve patient outcomes.
Side-by-side fundamentals
| Metric | PRCT | TFX | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $17.90 | $124.19 | |
| Market cap | $1.0B | $5.3B | |
| Net margin FY2025, SEC XBRL | -31.0% | -45.4% | PRCT higher |
| Gross margin FY2025, SEC XBRL | +63.7% | +56.2% | PRCT higher |
| Operating margin FY2025, SEC XBRL | -33.7% | +5.9% | TFX higher |
| ROE FY2025, SEC XBRL | -26.1% | -29.0% | PRCT higher |
| ROA FY2025, SEC XBRL | -18.8% | -13.0% | TFX higher |
| Debt / equity as of 2026-09-02 | 0.15 | 0.97 | PRCT lower |
| Revenue growth (YoY) as of 2026-09-02 | +22.7% | -14.5% | PRCT higher |
| Revenue CAGR (3y) SEC XBRL | +60.1% | -10.6% | PRCT higher |
| Dividend yield as of 2026-09-02 | n/a | +1.1% | |
| Dividend streak (yrs) SEC XBRL | 0 | 18 | TFX higher |
| Beta as of 2026-09-02 | 1.05 | 0.74 | |
| 1-year return as of 2026-10-08 close | -48.5% | -3.3% | TFX higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.